Search the Newsreel

Nektar Therapeutics Q2 Earnings Call Highlights

Nektar Therapeutics announced the initiation of its global Phase III ZENITH AD program for rezpegaldesleukin (REZPEG) in moderate-to-severe atopic dermatitis, with top-line data expected in mid-2028 and a potential BLA submission in 2029. The company also finalized plans for a registrational Phase III trial …

Two Seas Capital group (NKTR) reports 9.1% Nektar Therapeutics ownership via investment funds

Two Seas Capital group, including Two Seas Capital LP, Two Seas Capital GP LLC, and Sina Toussi, has reported a 9.1% beneficial ownership stake in Nektar Therapeutics (NKTR). As of June 30, 2026, they collectively own 3,092,234 shares of common stock through investment funds, …

Nektar Therapeutics (NKTR) Stock Looks Stretched Despite New Phase 3 Trial Launch

Nektar Q2 Earnings Beat Estimates, Revenues Lag, Pipeline in Focus

Nektar Therapeutics NKTR reported a loss of $1.23 per share for the second quarter of 2026, much narrower than the Zacks Consensus Estimate of a loss of $2.06. In the year-ago quarter, the company had incurred a loss of $2.95 cents per share. Total …

Is Phase III Rezpegaldesleukin And Cash Runway Progress Altering The Investment Case For Nektar Therapeutics (NKTR)?

Nektar Therapeutics (NKTR) adds $1.02B cash while posting $85.5M loss

Nektar: Q2 Earnings Snapshot

The article provides a snapshot of Nektar's Q2 earnings. No specific financial details are available in the provided content, as the main article text was not included.

Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan

Earnings Call Insights: Nektar Therapeutics (NKTR) Q2 2026 MANAGEMENT VIEW * “In July, we achieved yet another important milestone in Nektar with the initiation of the global ZENITH AD program, Phase III AD program for rezpegaldesleukin” (CEO, President & Director Howard W. Robin). “With …

Earnings call transcript: Nektar beats Q2 2026 EPS but stock slips after hours

Nektar Therapeutics reported better-than-expected Q2 2026 EPS but a slight revenue miss, causing its stock to slip after hours. The company maintains a strong cash position of over $1 billion, funding clinical development into 2028, and is advancing its lead pipeline asset, REZPEG, through …

Nektar Therapeutics (NASDAQ:NKTR) Announces Earnings Results, Beats Expectations By $0.74 EPS

Nektar Therapeutics (NKTR) Reports Q2 Loss, Misses Revenue Estimates

NEKTAR THERAPEUTICS ($NKTR) Releases Q2 2026 Earnings

Nektar Therapeutics Announces Second Quarter 2026 Financial Results

Nektar earnings in focus as Phase 3 trial launch raises stakes

Nektar Therapeutics is preparing to report second-quarter results, with analysts anticipating a loss of $2.00 per share on revenues of $10.38 million. The report comes as the company launched two pivotal Phase 3 trials for its lead drug candidate, rezpegaldesleukin, drawing investor attention to …

Is Nektar Therapeutics (NKTR) Still Below Fair Value After Its Recent Run Up?

Nektar Therapeutics (NKTR) has experienced significant stock momentum, with year-to-date returns of 75.1% and a 1-year total shareholder return of 195.61%, despite a negative five-year record. The company's stock, currently at $76.03, is considered undervalued by one narrative, with a fair value of $153.25, …

Nektar Therapeutics (NASDAQ:NKTR) Given Consensus Rating of "Moderate Buy" by Brokerages

Nektar Therapeutics (NASDAQ:NKTR) has received a "Moderate Buy" consensus rating from twelve analysts, with an average 12-month price target of $150.00. The company's shares opened at $75.50, and institutional investors own 75.88% of the stock. Insider selling has also been noted, with executives selling …

NKTR Stock Soars After Nektar Reports Positive Atopic Dermatitis Trial Results

Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm

Kuehn Law is investigating Nektar Therapeutics (NASDAQ: NKTR) following a federal securities lawsuit alleging that the company misrepresented or failed to disclose issues with its REZOLVE-AA trial for its lead product candidate. The lawsuit claims that enrollment did not follow protocol standards, which was …

Bronstein, Gewirtz & Grossman, LLC Is Investigating Nektar Therapeutics (NKTR) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Nektar Therapeutics (NKTR) on behalf of investors who purchased securities before February 26, 2025, and still hold them. The investigation aims to determine if Nektar's officers and/or directors engaged in corporate wrongdoing. The firm …

Lawsuit alleges Nektar Therapeutics misled investors on clinical trial integrity.

Kuehn Law is investigating Nektar Therapeutics over allegations that the company misled shareholders regarding the integrity of its REZOLVE-AA clinical trial. The lawsuit claims Nektar Therapeutics failed to adhere to trial protocols, overstated the trial's validity, and made false public statements. This could negatively …

Nektar Therapeutics $NKTR Shares Sold by Renaissance Technologies LLC

Bronstein, Gewirtz & Grossman, LLC Encourages Nektar Therapeutics (NKTR) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Nektar Therapeutics (NASDAQ:NKTR). The investigation concerns whether Nektar and certain officers engaged in corporate wrongdoing. Investors who purchased Nektar securities prior to February 26, 2025, and continue to hold them, …

CCORF Maintains Nektar Therapeutics(NKTR.US) With Buy Rating, Maintains Target Price $153

CCORF has reiterated its Buy rating on Nektar Therapeutics (NKTR.US) and maintained its target price at $153. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.

Is Global Phase 3 ZENITH AD Rezpegaldesleukin Program Altering The Investment Case For Nektar Therapeutics (NKTR)?

Nektar Therapeutics has initiated two global Phase 3 trials, ZENITH AD‑1 and ZENITH AD‑2, for its drug rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis. This development is seen as a crucial step for the company, potentially reshaping its investment narrative by providing a near-term …

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Nektar Therapeutics (NKTR) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Nektar Therapeutics (NKTR) regarding potential corporate wrongdoing by its officers and directors. The firm is encouraging investors who purchased Nektar securities before February 26, 2025, and still hold them, to join the investigation. Bronstein, …

Enterprise value to EBIT forward of Nektar Therapeutics – NASDAQ:NKTR

This article presents financial data for Nektar Therapeutics (NASDAQ: NKTR), specifically focusing on its enterprise value to EBIT forward. The data is provided by TradingView, indicating that the market for NKTR was closed at the time of publication with no trades. The content highlights …

Vanguard Capital Management (NKTR) discloses 5.17% beneficial stake in Nektar

Vanguard Capital Management has reported a beneficial ownership of 5.17% in Nektar Therapeutics (NKTR) common stock as of June 30, 2026. This stake, totaling 1,747,653 shares, includes holdings in Vanguard funds and managed accounts. Vanguard exercises sole voting power over 250,804 shares and sole …

Nektar Therapeutics (NKTR) Expected to Post Quarterly Earnings on Thursday

Nektar Therapeutics $NKTR Shares Acquired by Swiss National Bank

BlackRock (NYSE: BLK) discloses 7.8% beneficial stake in Nektar Therapeutics (NKTR)

BlackRock, Inc. has disclosed a 7.8% beneficial ownership stake in Nektar Therapeutics (NKTR), amounting to 2,643,796 shares of common stock as of June 30, 2026. This ownership was reported via a Schedule 13G filing, indicating that BlackRock holds sole voting power over 2,590,855 shares …

Nektar Therapeutics to Announce Financial Results for the Second Quarter on Thursday, August 13, 2026, After Close of U.S.-Based Financial Markets

Nektar Therapeutics will announce its second-quarter financial results on Thursday, August 13, 2026, after the close of U.S.-based financial markets. President and CEO Howard Robin will host a conference call at 5:00 p.m. ET/2:00 p.m. PT to discuss the results. An audio-only webcast will …

Nektar CEO Will Review Second-Quarter Results in Aug. 13 Webcast

Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter ended June 30, 2026, on Thursday, August 13, 2026, after the close of U.S. financial markets. CEO Howard Robin will host a conference call at 5:00 p.m. ET / 2:00 p.m. …

Nektar Therapeutics Q2 Results: Earnings date set for Aug 13

Nektar Therapeutics (Nasdaq: NKTR) is scheduled to release its second-quarter 2026 financial results on August 13, 2026, after the U.S. markets close. CEO Howard Robin will lead a conference call at 5:00 p.m. ET to discuss the results, the company's financial health, and advancements …